Posted by Michael Wonder on 15 Feb 2021
Xeris Pharmaceuticals receives European Commission approval of Ogluo (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus
12 February 2021 - Ogluo Europe’s first and only ready-to-use liquid glucagon for rescue.
Xeris Pharmaceuticals today announced that the European Commission has approved Ogluo (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.
